Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (75)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Change in physical activity related to admission for exacerbation in COPD patients

    Respiratory Medicine, Vol. 212

  3. Characteristics and management of patients with SARS-CoV2 infection admitted to pediatric intensive care units: Data analysis of the Spanish national multicenter registry

    Pediatric Pulmonology, Vol. 58, Núm. 10, pp. 2916-2929

  4. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  5. Correction to: Predictors of short‑term COPD readmission (Internal and Emergency Medicine, (2022), 17, 5, (1481-1490), 10.1007/s11739-022-02948-4)

    Internal and Emergency Medicine

  6. Development of Antimicrobial Defined Daily Dose (DDD) for the Pediatric Population

    Antibiotics, Vol. 12, Núm. 2

  7. Gradient diffusion strips for detecting azole resistance in Aspergillus fumigatus sensu lato

    Mycoses, Vol. 66, Núm. 3, pp. 196-201

  8. Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 77, Núm. 9, pp. 1273-1281

  9. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice

    Transplantation, Vol. 107, Núm. 3, pp. 762-773

  10. Physical activity and sedentary behaviour in patients admitted with COPD: Associated factors

    Respiratory Medicine and Research, Vol. 84

  11. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

    The Lancet Regional Health - Europe, Vol. 28

  12. Treatments for multi-system inflammatory syndrome in children — discharge, fever, and second-line therapies

    European Journal of Pediatrics, Vol. 182, Núm. 1, pp. 461-466